Sudeep Pharma Ltd.
Sudeep Pharma Ltd. (SUDEEPPHRM.NS) Stock Competitors & Peer Comparison
See (SUDEEPPHRM.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUDEEPPHRM.NS | ₹685.80 | -3.07% | 77.9B | 46.43 | ₹14.86 | N/A |
| SUNPHARMA.BO | ₹1,821.50 | +0.74% | 4.4T | 40.09 | ₹45.50 | +0.90% |
| SUNPHARMA.NS | ₹1,818.00 | +0.54% | 4.4T | 40.02 | ₹45.57 | +0.90% |
| DIVISLAB.NS | ₹6,670.00 | +2.58% | 1.8T | 70.69 | ₹93.64 | +0.45% |
| DIVISLAB.BO | ₹6,656.50 | +2.32% | 1.8T | 70.65 | ₹93.68 | +0.45% |
| TORNTPHARM.BO | ₹4,266.95 | +1.80% | 1.4T | 67.23 | ₹63.25 | +0.82% |
| TORNTPHARM.NS | ₹4,290.00 | +2.51% | 1.4T | 63.50 | ₹66.96 | +0.82% |
| LUPIN.BO | ₹2,340.20 | +1.58% | 1.1T | 24.91 | ₹94.37 | +0.51% |
| LUPIN.NS | ₹2,337.20 | +1.39% | 1.1T | 23.16 | ₹101.43 | +0.51% |
| DRREDDY.BO | ₹1,271.00 | -3.93% | 1.1T | 18.99 | ₹67.84 | +1.24% |
Stock Comparison
SUDEEPPHRM.NS vs SUNPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUNPHARMA.BO trades at ₹1,821.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUNPHARMA.BO's P/E ratio is 40.09. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUNPHARMA.BO's competition here
SUDEEPPHRM.NS vs SUNPHARMA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUNPHARMA.NS trades at ₹1,818.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUNPHARMA.NS's P/E ratio is 40.02. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUNPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUNPHARMA.NS's competition here
SUDEEPPHRM.NS vs DIVISLAB.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while DIVISLAB.NS trades at ₹6,670.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas DIVISLAB.NS's P/E ratio is 70.69. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DIVISLAB.NS's competition here
SUDEEPPHRM.NS vs DIVISLAB.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while DIVISLAB.BO trades at ₹6,656.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas DIVISLAB.BO's P/E ratio is 70.65. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DIVISLAB.BO's competition here
SUDEEPPHRM.NS vs TORNTPHARM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while TORNTPHARM.BO trades at ₹4,266.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas TORNTPHARM.BO's P/E ratio is 67.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check TORNTPHARM.BO's competition here
SUDEEPPHRM.NS vs TORNTPHARM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while TORNTPHARM.NS trades at ₹4,290.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas TORNTPHARM.NS's P/E ratio is 63.50. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check TORNTPHARM.NS's competition here
SUDEEPPHRM.NS vs LUPIN.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while LUPIN.BO trades at ₹2,340.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas LUPIN.BO's P/E ratio is 24.91. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LUPIN.BO's competition here
SUDEEPPHRM.NS vs LUPIN.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while LUPIN.NS trades at ₹2,337.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas LUPIN.NS's P/E ratio is 23.16. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LUPIN.NS's competition here
SUDEEPPHRM.NS vs DRREDDY.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while DRREDDY.BO trades at ₹1,271.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas DRREDDY.BO's P/E ratio is 18.99. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to DRREDDY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DRREDDY.BO's competition here
SUDEEPPHRM.NS vs DRREDDY.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while DRREDDY.NS trades at ₹1,272.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas DRREDDY.NS's P/E ratio is 18.97. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check DRREDDY.NS's competition here
SUDEEPPHRM.NS vs MANKIND.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, MANKIND.BO has a market cap of 933.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while MANKIND.BO trades at ₹2,324.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas MANKIND.BO's P/E ratio is 52.41. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MANKIND.BO's competition here
SUDEEPPHRM.NS vs MANKIND.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, MANKIND.NS has a market cap of 932.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while MANKIND.NS trades at ₹2,327.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas MANKIND.NS's P/E ratio is 52.34. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check MANKIND.NS's competition here
SUDEEPPHRM.NS vs ZYDUSLIFE.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ZYDUSLIFE.NS has a market cap of 908B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ZYDUSLIFE.NS trades at ₹915.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ZYDUSLIFE.NS's P/E ratio is 18.40. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ZYDUSLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ZYDUSLIFE.NS's competition here
SUDEEPPHRM.NS vs ZYDUSLIFE.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ZYDUSLIFE.BO has a market cap of 907.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ZYDUSLIFE.BO trades at ₹913.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ZYDUSLIFE.BO's P/E ratio is 18.39. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ZYDUSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ZYDUSLIFE.BO's competition here
SUDEEPPHRM.NS vs AUROPHARMA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AUROPHARMA.NS has a market cap of 799.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AUROPHARMA.NS trades at ₹1,429.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AUROPHARMA.NS's P/E ratio is 22.92. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AUROPHARMA.NS's competition here
SUDEEPPHRM.NS vs AUROPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AUROPHARMA.BO has a market cap of 799.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AUROPHARMA.BO trades at ₹1,429.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AUROPHARMA.BO's P/E ratio is 23.36. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AUROPHARMA.BO's competition here
SUDEEPPHRM.NS vs GLENMARK.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GLENMARK.NS has a market cap of 675.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GLENMARK.NS trades at ₹2,427.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GLENMARK.NS's P/E ratio is 63.36. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLENMARK.NS's competition here
SUDEEPPHRM.NS vs GLENMARK.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GLENMARK.BO has a market cap of 675.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GLENMARK.BO trades at ₹2,425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GLENMARK.BO's P/E ratio is 63.35. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLENMARK.BO's competition here
SUDEEPPHRM.NS vs ALKEM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ALKEM.NS has a market cap of 640.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ALKEM.NS trades at ₹5,404.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ALKEM.NS's P/E ratio is 27.05. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALKEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALKEM.NS's competition here
SUDEEPPHRM.NS vs ALKEM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ALKEM.BO has a market cap of 640.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ALKEM.BO trades at ₹5,406.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ALKEM.BO's P/E ratio is 27.00. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALKEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALKEM.BO's competition here
SUDEEPPHRM.NS vs LAURUSLABS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, LAURUSLABS.BO has a market cap of 629.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while LAURUSLABS.BO trades at ₹1,164.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas LAURUSLABS.BO's P/E ratio is 74.73. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LAURUSLABS.BO's competition here
SUDEEPPHRM.NS vs LAURUSLABS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, LAURUSLABS.NS has a market cap of 629.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while LAURUSLABS.NS trades at ₹1,162.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas LAURUSLABS.NS's P/E ratio is 74.63. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check LAURUSLABS.NS's competition here
SUDEEPPHRM.NS vs SUVENPHAR.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVENPHAR.NS's competition here
SUDEEPPHRM.NS vs SUVENPHAR.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVENPHAR.BO's competition here
SUDEEPPHRM.NS vs IPCALAB.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, IPCALAB.BO has a market cap of 388.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while IPCALAB.BO trades at ₹1,535.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas IPCALAB.BO's P/E ratio is 42.72. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IPCALAB.BO's competition here
SUDEEPPHRM.NS vs IPCALAB.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, IPCALAB.NS has a market cap of 388.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while IPCALAB.NS trades at ₹1,536.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas IPCALAB.NS's P/E ratio is 42.71. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IPCALAB.NS's competition here
SUDEEPPHRM.NS vs AJANTPHARM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AJANTPHARM.BO has a market cap of 362.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AJANTPHARM.BO trades at ₹2,900.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AJANTPHARM.BO's P/E ratio is 35.81. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AJANTPHARM.BO's competition here
SUDEEPPHRM.NS vs AJANTPHARM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AJANTPHARM.NS has a market cap of 362.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AJANTPHARM.NS trades at ₹2,902.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AJANTPHARM.NS's P/E ratio is 35.68. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AJANTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AJANTPHARM.NS's competition here
SUDEEPPHRM.NS vs EMCURE.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, EMCURE.NS has a market cap of 340B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while EMCURE.NS trades at ₹1,689.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas EMCURE.NS's P/E ratio is 39.09. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check EMCURE.NS's competition here
SUDEEPPHRM.NS vs JBCHEPHARM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, JBCHEPHARM.NS has a market cap of 334.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while JBCHEPHARM.NS trades at ₹2,106.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas JBCHEPHARM.NS's P/E ratio is 43.92. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JBCHEPHARM.NS's competition here
SUDEEPPHRM.NS vs JBCHEPHARM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, JBCHEPHARM.BO has a market cap of 333.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while JBCHEPHARM.BO trades at ₹2,093.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas JBCHEPHARM.BO's P/E ratio is 43.74. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JBCHEPHARM.BO's competition here
SUDEEPPHRM.NS vs PEL.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PEL.NS's competition here
SUDEEPPHRM.NS vs WOCKPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, WOCKPHARMA.BO has a market cap of 231.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while WOCKPHARMA.BO trades at ₹1,542.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas WOCKPHARMA.BO's P/E ratio is 1131.35. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check WOCKPHARMA.BO's competition here
SUDEEPPHRM.NS vs WOCKPHARMA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, WOCKPHARMA.NS has a market cap of 231.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while WOCKPHARMA.NS trades at ₹1,550.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas WOCKPHARMA.NS's P/E ratio is 1130.95. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check WOCKPHARMA.NS's competition here
SUDEEPPHRM.NS vs PPLPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, PPLPHARMA.BO has a market cap of 212.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while PPLPHARMA.BO trades at ₹159.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas PPLPHARMA.BO's P/E ratio is -65.16. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PPLPHARMA.BO's competition here
SUDEEPPHRM.NS vs NEULANDLAB.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NEULANDLAB.BO has a market cap of 207B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NEULANDLAB.BO trades at ₹16,209.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NEULANDLAB.BO's P/E ratio is 115.68. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NEULANDLAB.BO's competition here
SUDEEPPHRM.NS vs NEULANDLAB.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NEULANDLAB.NS has a market cap of 206.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NEULANDLAB.NS trades at ₹16,199.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NEULANDLAB.NS's P/E ratio is 115.56. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NEULANDLAB.NS's competition here
SUDEEPPHRM.NS vs ASTRAZEN.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ASTRAZEN.BO has a market cap of 201.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ASTRAZEN.BO trades at ₹8,240.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ASTRAZEN.BO's P/E ratio is 99.92. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ASTRAZEN.BO's competition here
SUDEEPPHRM.NS vs ASTRAZEN.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ASTRAZEN.NS has a market cap of 201.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ASTRAZEN.NS trades at ₹8,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ASTRAZEN.NS's P/E ratio is 99.96. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ASTRAZEN.NS's competition here
SUDEEPPHRM.NS vs NATCOPHARM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NATCOPHARM.NS has a market cap of 199.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NATCOPHARM.NS trades at ₹1,132.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NATCOPHARM.NS's P/E ratio is 12.83. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NATCOPHARM.NS's competition here
SUDEEPPHRM.NS vs NATCOPHARM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NATCOPHARM.BO has a market cap of 199.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NATCOPHARM.BO trades at ₹1,123.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NATCOPHARM.BO's P/E ratio is 12.96. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NATCOPHARM.BO's competition here
SUDEEPPHRM.NS vs ERIS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ERIS.BO has a market cap of 187.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ERIS.BO trades at ₹1,353.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ERIS.BO's P/E ratio is 42.84. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ERIS.BO's competition here
SUDEEPPHRM.NS vs ERIS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ERIS.NS has a market cap of 187.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ERIS.NS trades at ₹1,356.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ERIS.NS's P/E ratio is 42.99. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ERIS.NS's competition here
SUDEEPPHRM.NS vs COHANCE.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, COHANCE.NS has a market cap of 180.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while COHANCE.NS trades at ₹454.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas COHANCE.NS's P/E ratio is 92.85. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check COHANCE.NS's competition here
SUDEEPPHRM.NS vs COHANCE.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, COHANCE.BO has a market cap of 179.8B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while COHANCE.BO trades at ₹453.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas COHANCE.BO's P/E ratio is 92.69. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check COHANCE.BO's competition here
SUDEEPPHRM.NS vs GRANULES.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GRANULES.NS has a market cap of 174.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GRANULES.NS trades at ₹714.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GRANULES.NS's P/E ratio is 28.72. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GRANULES.NS's competition here
SUDEEPPHRM.NS vs GRANULES.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GRANULES.BO has a market cap of 170.7B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GRANULES.BO trades at ₹712.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GRANULES.BO's P/E ratio is 31.28. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GRANULES.BO's competition here
SUDEEPPHRM.NS vs APLLTD.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, APLLTD.NS has a market cap of 150.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while APLLTD.NS trades at ₹770.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas APLLTD.NS's P/E ratio is 23.86. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check APLLTD.NS's competition here
SUDEEPPHRM.NS vs APLLTD.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, APLLTD.BO has a market cap of 150.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while APLLTD.BO trades at ₹771.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas APLLTD.BO's P/E ratio is 23.85. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check APLLTD.BO's competition here
SUDEEPPHRM.NS vs JUBLPHARMA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, JUBLPHARMA.NS has a market cap of 147.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while JUBLPHARMA.NS trades at ₹945.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas JUBLPHARMA.NS's P/E ratio is 34.19. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JUBLPHARMA.NS's competition here
SUDEEPPHRM.NS vs JUBLPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, JUBLPHARMA.BO has a market cap of 147.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while JUBLPHARMA.BO trades at ₹939.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas JUBLPHARMA.BO's P/E ratio is 34.14. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check JUBLPHARMA.BO's competition here
SUDEEPPHRM.NS vs GLS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLS.NS's competition here
SUDEEPPHRM.NS vs GLS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GLS.BO's competition here
SUDEEPPHRM.NS vs CAPLIPOINT.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, CAPLIPOINT.NS has a market cap of 132B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while CAPLIPOINT.NS trades at ₹1,737.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas CAPLIPOINT.NS's P/E ratio is 21.57. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPLIPOINT.NS's competition here
SUDEEPPHRM.NS vs CAPLIPOINT.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, CAPLIPOINT.BO has a market cap of 131.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while CAPLIPOINT.BO trades at ₹1,747.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas CAPLIPOINT.BO's P/E ratio is 21.55. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPLIPOINT.BO's competition here
SUDEEPPHRM.NS vs ALIVUS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ALIVUS.NS has a market cap of 131.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ALIVUS.NS trades at ₹1,078.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ALIVUS.NS's P/E ratio is 24.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALIVUS.NS's competition here
SUDEEPPHRM.NS vs ALIVUS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ALIVUS.BO has a market cap of 131.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ALIVUS.BO trades at ₹1,071.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ALIVUS.BO's P/E ratio is 24.16. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALIVUS.BO's competition here
SUDEEPPHRM.NS vs CAPPL.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check CAPPL.BO's competition here
SUDEEPPHRM.NS vs STAR.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, STAR.NS has a market cap of 95.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while STAR.NS trades at ₹1,056.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas STAR.NS's P/E ratio is 18.60. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check STAR.NS's competition here
SUDEEPPHRM.NS vs STAR.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, STAR.BO has a market cap of 95.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while STAR.BO trades at ₹1,052.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas STAR.BO's P/E ratio is 18.60. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check STAR.BO's competition here
SUDEEPPHRM.NS vs VIYASH.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, VIYASH.NS has a market cap of 89.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while VIYASH.NS trades at ₹200.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas VIYASH.NS's P/E ratio is 79.07. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check VIYASH.NS's competition here
SUDEEPPHRM.NS vs AKUMS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AKUMS.NS has a market cap of 85.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AKUMS.NS trades at ₹553.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AKUMS.NS's P/E ratio is 26.74. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AKUMS.NS's competition here
SUDEEPPHRM.NS vs PGHL.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, PGHL.NS has a market cap of 85.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while PGHL.NS trades at ₹5,181.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas PGHL.NS's P/E ratio is 36.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PGHL.NS's competition here
SUDEEPPHRM.NS vs PGHL.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, PGHL.BO has a market cap of 85.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while PGHL.BO trades at ₹5,158.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas PGHL.BO's P/E ratio is 36.19. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, SUDEEPPHRM.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check PGHL.BO's competition here
SUDEEPPHRM.NS vs SHILPAMED.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SHILPAMED.NS has a market cap of 81.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SHILPAMED.NS trades at ₹413.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SHILPAMED.NS's P/E ratio is 37.05. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SHILPAMED.NS's competition here
SUDEEPPHRM.NS vs AARTIPHARM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AARTIPHARM.NS has a market cap of 73.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AARTIPHARM.NS trades at ₹770.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AARTIPHARM.NS's P/E ratio is 34.24. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIPHARM.NS's competition here
SUDEEPPHRM.NS vs AARTIPHARM.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AARTIPHARM.BO has a market cap of 73B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AARTIPHARM.BO trades at ₹767.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AARTIPHARM.BO's P/E ratio is 34.15. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIPHARM.BO's competition here
SUDEEPPHRM.NS vs FDC.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, FDC.BO has a market cap of 60.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while FDC.BO trades at ₹367.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas FDC.BO's P/E ratio is 27.95. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check FDC.BO's competition here
SUDEEPPHRM.NS vs FDC.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, FDC.NS has a market cap of 60.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while FDC.NS trades at ₹367.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas FDC.NS's P/E ratio is 27.96. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check FDC.NS's competition here
SUDEEPPHRM.NS vs SEQUENT.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SEQUENT.NS's competition here
SUDEEPPHRM.NS vs SEQUENT.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SEQUENT.BO's competition here
SUDEEPPHRM.NS vs SUVEN.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUVEN.BO has a market cap of 49.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUVEN.BO trades at ₹207.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUVEN.BO's P/E ratio is -17.28. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVEN.BO's competition here
SUDEEPPHRM.NS vs INNOVACAP.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, INNOVACAP.NS has a market cap of 48.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while INNOVACAP.NS trades at ₹870.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas INNOVACAP.NS's P/E ratio is 36.46. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check INNOVACAP.NS's competition here
SUDEEPPHRM.NS vs SUVEN.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SUVEN.NS has a market cap of 47.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SUVEN.NS trades at ₹206.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SUVEN.NS's P/E ratio is -17.26. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SUVEN.NS's competition here
SUDEEPPHRM.NS vs SPARC.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SPARC.BO has a market cap of 45.4B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SPARC.BO trades at ₹140.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SPARC.BO's P/E ratio is -16.92. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SPARC.BO's competition here
SUDEEPPHRM.NS vs SPARC.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SPARC.NS has a market cap of 45.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SPARC.NS trades at ₹140.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SPARC.NS's P/E ratio is -16.93. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SPARC.NS's competition here
SUDEEPPHRM.NS vs SHILPAMED.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SHILPAMED.BO has a market cap of 40.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SHILPAMED.BO trades at ₹425.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SHILPAMED.BO's P/E ratio is 37.02. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SHILPAMED.BO's competition here
SUDEEPPHRM.NS vs GUJTHEM.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GUJTHEM.NS has a market cap of 40.6B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GUJTHEM.NS trades at ₹385.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GUJTHEM.NS's P/E ratio is 84.61. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUJTHEM.NS's competition here
SUDEEPPHRM.NS vs RPGLIFE.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, RPGLIFE.BO has a market cap of 40.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while RPGLIFE.BO trades at ₹2,322.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas RPGLIFE.BO's P/E ratio is 19.79. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check RPGLIFE.BO's competition here
SUDEEPPHRM.NS vs RPGLIFE.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, RPGLIFE.NS has a market cap of 40B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while RPGLIFE.NS trades at ₹2,319.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas RPGLIFE.NS's P/E ratio is 19.72. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check RPGLIFE.NS's competition here
SUDEEPPHRM.NS vs AARTIDRUGS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AARTIDRUGS.NS has a market cap of 36.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AARTIDRUGS.NS trades at ₹391.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AARTIDRUGS.NS's P/E ratio is 17.89. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIDRUGS.NS's competition here
SUDEEPPHRM.NS vs AARTIDRUGS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, AARTIDRUGS.BO has a market cap of 36B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while AARTIDRUGS.BO trades at ₹391.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas AARTIDRUGS.BO's P/E ratio is 17.84. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check AARTIDRUGS.BO's competition here
SUDEEPPHRM.NS vs ORCHPHARMA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ORCHPHARMA.NS has a market cap of 31.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ORCHPHARMA.NS trades at ₹629.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ORCHPHARMA.NS's P/E ratio is 167.79. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ORCHPHARMA.NS's competition here
SUDEEPPHRM.NS vs ORCHPHARMA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ORCHPHARMA.BO trades at ₹626.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ORCHPHARMA.BO's P/E ratio is 166.82. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ORCHPHARMA.BO's competition here
SUDEEPPHRM.NS vs GUFICBIO.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GUFICBIO.BO has a market cap of 29.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GUFICBIO.BO trades at ₹287.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GUFICBIO.BO's P/E ratio is 58.59. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUFICBIO.BO's competition here
SUDEEPPHRM.NS vs GUFICBIO.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, GUFICBIO.NS has a market cap of 29.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while GUFICBIO.NS trades at ₹289.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas GUFICBIO.NS's P/E ratio is 58.68. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check GUFICBIO.NS's competition here
SUDEEPPHRM.NS vs BLISSGVS.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, BLISSGVS.BO has a market cap of 29B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while BLISSGVS.BO trades at ₹270.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas BLISSGVS.BO's P/E ratio is 26.93. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check BLISSGVS.BO's competition here
SUDEEPPHRM.NS vs BLISSGVS.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, BLISSGVS.NS has a market cap of 29B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while BLISSGVS.NS trades at ₹269.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas BLISSGVS.NS's P/E ratio is 26.93. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check BLISSGVS.NS's competition here
SUDEEPPHRM.NS vs IOLCP.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, IOLCP.NS has a market cap of 27.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while IOLCP.NS trades at ₹94.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas IOLCP.NS's P/E ratio is 24.05. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IOLCP.NS's competition here
SUDEEPPHRM.NS vs IOLCP.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, IOLCP.BO has a market cap of 27.9B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while IOLCP.BO trades at ₹94.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas IOLCP.BO's P/E ratio is 24.04. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check IOLCP.BO's competition here
SUDEEPPHRM.NS vs UNICHEMLAB.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, UNICHEMLAB.BO has a market cap of 27.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while UNICHEMLAB.BO trades at ₹374.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas UNICHEMLAB.BO's P/E ratio is 9.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check UNICHEMLAB.BO's competition here
SUDEEPPHRM.NS vs UNICHEMLAB.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, UNICHEMLAB.NS has a market cap of 27.1B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while UNICHEMLAB.NS trades at ₹374.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas UNICHEMLAB.NS's P/E ratio is 9.21. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check UNICHEMLAB.NS's competition here
SUDEEPPHRM.NS vs NOVARTIND.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NOVARTIND.NS has a market cap of 25.3B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NOVARTIND.NS trades at ₹1,038.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NOVARTIND.NS's P/E ratio is 26.07. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NOVARTIND.NS's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NOVARTIND.NS's competition here
SUDEEPPHRM.NS vs NOVARTIND.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, NOVARTIND.BO has a market cap of 25.2B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while NOVARTIND.BO trades at ₹1,035.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas NOVARTIND.BO's P/E ratio is 25.97. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check NOVARTIND.BO's competition here
SUDEEPPHRM.NS vs SOLARA.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SOLARA.NS has a market cap of 25B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SOLARA.NS trades at ₹502.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SOLARA.NS's P/E ratio is -107.89. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SOLARA.NS's competition here
SUDEEPPHRM.NS vs SOLARA.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, SOLARA.BO has a market cap of 25B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while SOLARA.BO trades at ₹501.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas SOLARA.BO's P/E ratio is -108.23. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check SOLARA.BO's competition here
SUDEEPPHRM.NS vs HIKAL.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, HIKAL.NS has a market cap of 24B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while HIKAL.NS trades at ₹196.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas HIKAL.NS's P/E ratio is -183.70. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check HIKAL.NS's competition here
SUDEEPPHRM.NS vs HIKAL.BO Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, HIKAL.BO has a market cap of 24B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while HIKAL.BO trades at ₹196.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas HIKAL.BO's P/E ratio is 243.31. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check HIKAL.BO's competition here
SUDEEPPHRM.NS vs ALEMBICLTD.NS Comparison May 2026
SUDEEPPHRM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUDEEPPHRM.NS stands at 77.9B. In comparison, ALEMBICLTD.NS has a market cap of 23.5B. Regarding current trading prices, SUDEEPPHRM.NS is priced at ₹685.80, while ALEMBICLTD.NS trades at ₹91.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUDEEPPHRM.NS currently has a P/E ratio of 46.43, whereas ALEMBICLTD.NS's P/E ratio is 7.37. In terms of profitability, SUDEEPPHRM.NS's ROE is N/A, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, SUDEEPPHRM.NS is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUDEEPPHRM.NS.Check ALEMBICLTD.NS's competition here